Daniel C Beachler1, Raphael Viscidi, Elizabeth A Sugar, Howard Minkoff, Howard D Strickler, Ross D Cranston, Dorothy J Wiley, Lisa P Jacobson, Kathleen M Weber, Joseph B Margolick, Susheel Reddy, Maura L Gillison, Gypsyamber D'Souza. 1. From the *Departments of Epidemiology, †Molecular Microbiology and Immunology, and ‡Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; §Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY; ¶Departments of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY; ∥Department of Medicine, University of Pittsburgh, Pittsburgh, PA; **School of Nursing, University of California-Los Angeles, Los Angeles, CA; ††Hektoen Institute of Medicine, The CORE Center at John H. Stroger Jr Hospital of Cook County, Chicago, IL; ‡‡Department of Infectious Disease, Northwestern University, Chicago, IL; and §§Viral Oncology Program, Ohio State University Comprehensive Cancer Center, Columbus, OH.
Abstract
BACKGROUND: Individuals with human papillomavirus (HPV) infections can develop IgG antibodies to HPV proteins including the L1 capsid and E6 and E7 oncoproteins. Evidence on whether L1 antibodies reduce the risk of cervical HPV infection is mixed, but this has not been explored for oral HPV infections. Antibodies to HPV16's E6 oncoprotein have been detected in some oropharyngeal cancer cases years before cancer diagnosis, but it is unknown if these antibodies are associated with oral HPV16 DNA. METHODS: Enzyme-linked immunosorbent assays tested for serum antibodies to HPV16's L1 capsid in 463 HIV-infected and 293 HIV-uninfected adults, and for antibodies to recombinantly expressed E6 and E7 oncoproteins to HPV16 in 195 HIV-infected and 69 HIV-uninfected cancer-free participants at baseline. Oral rinse samples were collected semiannually for up to 3 years and tested for HPV DNA using PGMY 09/11 primers. Adjusted Poisson, logistic, and Wei-Lin-Weissfeld regression models were used. RESULTS: Human papillomavirus 16 L1 seroreactivity did not reduce the subsequent risk of incident oral HPV16 infection in unadjusted (hazard ratio, 1.4; 95% confidence interval, 0.59-3.3) or adjusted (adjusted hazard ratio = 1.1; 95% confidence interval, 0.41-3.0) analysis. Antibodies to HPV16 E6 and E7 oncoproteins were detected in 7.6% and 3.4% of participants, respectively, but they were not associated with baseline oral HPV16 DNA prevalence or oral HPV16 persistence (each P > 0.40). CONCLUSIONS: Naturally acquired HPV16 L1 antibodies did not reduce the risk of subsequent oral HPV16 infection. Human papillomavirus 16 E6 and E7 seropositivity was not a marker for oral HPV16 infection in this population without HPV-related cancer.
BACKGROUND: Individuals with humanpapillomavirus (HPV) infections can develop IgG antibodies to HPV proteins including the L1 capsid and E6 and E7 oncoproteins. Evidence on whether L1 antibodies reduce the risk of cervical HPV infection is mixed, but this has not been explored for oral HPV infections. Antibodies to HPV16's E6 oncoprotein have been detected in some oropharyngeal cancer cases years before cancer diagnosis, but it is unknown if these antibodies are associated with oral HPV16 DNA. METHODS: Enzyme-linked immunosorbent assays tested for serum antibodies to HPV16's L1 capsid in 463 HIV-infected and 293 HIV-uninfected adults, and for antibodies to recombinantly expressed E6 and E7 oncoproteins to HPV16 in 195 HIV-infected and 69 HIV-uninfected cancer-free participants at baseline. Oral rinse samples were collected semiannually for up to 3 years and tested for HPV DNA using PGMY 09/11 primers. Adjusted Poisson, logistic, and Wei-Lin-Weissfeld regression models were used. RESULTS:Human papillomavirus 16 L1 seroreactivity did not reduce the subsequent risk of incident oral HPV16 infection in unadjusted (hazard ratio, 1.4; 95% confidence interval, 0.59-3.3) or adjusted (adjusted hazard ratio = 1.1; 95% confidence interval, 0.41-3.0) analysis. Antibodies to HPV16 E6 and E7 oncoproteins were detected in 7.6% and 3.4% of participants, respectively, but they were not associated with baseline oral HPV16 DNA prevalence or oral HPV16 persistence (each P > 0.40). CONCLUSIONS: Naturally acquired HPV16 L1 antibodies did not reduce the risk of subsequent oral HPV16 infection. Human papillomavirus 16 E6 and E7 seropositivity was not a marker for oral HPV16 infection in this population without HPV-related cancer.
Authors: Nicolas Wentzensen; Ana Cecilia Rodriguez; Raphael Viscidi; Rolando Herrero; Allan Hildesheim; Arpita Ghosh; Jorge Morales; Sholom Wacholder; Diego Guillen; Mario Alfaro; Mahboobeh Safaeian; Robert D Burk; Mark Schiffman Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: Sofie H Mooij; Olivia Landén; Fiona R M van der Klis; Marianne A B van der Sande; Hester E de Melker; Roel A Coutinho; Arne van Eeden; Martijn S van Rooijen; Chris J L M Meijer; Maarten F Schim van der Loeff Journal: J Infect Date: 2014-06-12 Impact factor: 6.072
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Daniel C Beachler; Gypsyamber D'Souza; Elizabeth A Sugar; Wiehong Xiao; Maura L Gillison Journal: J Infect Dis Date: 2013-04-17 Impact factor: 5.226
Authors: Yuehan Zhang; Tim Waterboer; Michael Pawlita; Elizabeth Sugar; Howard Minkoff; Ross D Cranston; Dorothy Wiley; Robert Burk; Susheel Reddy; Joseph Margolick; Howard Strickler; Kathleen Weber; Maura Gillison; Gypsyamber D'Souza Journal: Cancer Epidemiol Date: 2016-06-23 Impact factor: 2.984
Authors: Christine M Pierce Campbell; Raphael P Viscidi; B Nelson Torres; Hui-Yi Lin; William Fulp; Martha Abrahamsen; Eduardo Lazcano-Ponce; Luisa L Villa; Aimée R Kreimer; Anna R Giuliano Journal: J Infect Dis Date: 2016-02-29 Impact factor: 5.226
Authors: Daniel C Beachler; Ligia A Pinto; Troy J Kemp; Alan G Nyitray; Allan Hildesheim; Raphael Viscidi; John Schussler; Aimée R Kreimer; Anna R Giuliano Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-02-23 Impact factor: 4.254
Authors: Anna R Giuliano; Raphael Viscidi; B Nelson Torres; Donna J Ingles; Staci L Sudenga; Luisa L Villa; Maria Luiza Baggio; Martha Abrahamsen; Manuel Quiterio; Jorge Salmeron; Eduardo Lazcano-Ponce Journal: Papillomavirus Res Date: 2015-12-01
Authors: Anna Rosa Garbuglia; Daniele Lapa; Catia Sias; Maria Rosaria Capobianchi; Paola Del Porto Journal: Front Immunol Date: 2020-02-18 Impact factor: 7.561